JP7762933B2 - 還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用 - Google Patents

還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用

Info

Publication number
JP7762933B2
JP7762933B2 JP2024550658A JP2024550658A JP7762933B2 JP 7762933 B2 JP7762933 B2 JP 7762933B2 JP 2024550658 A JP2024550658 A JP 2024550658A JP 2024550658 A JP2024550658 A JP 2024550658A JP 7762933 B2 JP7762933 B2 JP 7762933B2
Authority
JP
Japan
Prior art keywords
crystalline form
crystal
disodium salt
reduced
nicotinamide mononucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024550658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508874A5 (https=
JP2025508874A (ja
Inventor
省 高
建軍 余
強 沈
欽源 徐
銀山 李
佳玲 劉
留▲レイ▼ 常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effepharm (shanghai) Co Ltd
Original Assignee
Effepharm (shanghai) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effepharm (shanghai) Co Ltd filed Critical Effepharm (shanghai) Co Ltd
Publication of JP2025508874A publication Critical patent/JP2025508874A/ja
Publication of JP2025508874A5 publication Critical patent/JP2025508874A5/ja
Application granted granted Critical
Publication of JP7762933B2 publication Critical patent/JP7762933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
JP2024550658A 2022-02-23 2023-02-09 還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用 Active JP7762933B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210168280.1 2022-02-23
CN202210168280.1A CN115368423B (zh) 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
PCT/CN2023/075226 WO2023160405A1 (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Publications (3)

Publication Number Publication Date
JP2025508874A JP2025508874A (ja) 2025-04-10
JP2025508874A5 JP2025508874A5 (https=) 2025-07-11
JP7762933B2 true JP7762933B2 (ja) 2025-10-31

Family

ID=84060296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550658A Active JP7762933B2 (ja) 2022-02-23 2023-02-09 還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用

Country Status (9)

Country Link
US (1) US12570683B2 (https=)
EP (1) EP4484438A1 (https=)
JP (1) JP7762933B2 (https=)
KR (1) KR20240167631A (https=)
CN (2) CN115368423B (https=)
AU (1) AU2023223327B2 (https=)
CA (1) CA3244879A1 (https=)
NZ (1) NZ813980A (https=)
WO (1) WO2023160405A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368423B (zh) 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
WO2023179793A1 (zh) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法
CN119320416B (zh) * 2023-11-10 2026-01-06 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的多晶型及其制法和用途
CN119978042B (zh) * 2023-11-10 2025-09-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
WO2025142856A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドのカルシウム塩及びその製造方法
WO2025142857A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドの塩及びその製造方法
CN120424148B (zh) * 2024-02-02 2025-10-17 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸盐及其组合物、制法和用途
CN118546191A (zh) * 2024-07-29 2024-08-27 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸一钠盐晶型及其制备方法和应用
WO2026075119A1 (ja) * 2024-10-04 2026-04-09 株式会社カネカ 還元型ニコチンアミドモノヌクレオチドの製造方法
CN119143826B (zh) * 2024-11-19 2025-03-28 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸二钠盐无定型化合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016135750A (ja) 2015-01-23 2016-07-28 株式会社ベスビオ 化粧料
CN109350622A (zh) 2018-10-17 2019-02-19 深圳市龙格生技术有限公司 烟酰胺核糖及其衍生物与吡咯喹啉醌及其钠盐的组合工艺
WO2021098725A1 (en) 2019-11-19 2021-05-27 Tsinghua University Synthetic method for nmn derivative and medical applications of nmn and its derivative
CN113332304A (zh) 2021-06-08 2021-09-03 深圳市旷逸生物科技有限公司 烟酰胺单核苷酸在制备心肌缺血再灌注损伤药物中的应用
JP2021524865A (ja) 2018-05-15 2021-09-16 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗加齢剤としての、特に不妊症治療のためのニコチンアミドモノヌクレオチドの無機塩
JP2021533195A (ja) 2018-08-01 2021-12-02 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗老化剤としてのニコチン酸及びニコチンアミドモノヌクロエチド及びリボシドの四級アンモニウム塩
CN114075582A (zh) 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种d-核糖-5-磷酸的制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274357B1 (en) * 2015-03-27 2019-12-11 Cornell University Efficient synthesis of nicotinamide mononucleotide
CN110845548B (zh) * 2019-11-22 2021-02-09 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法
CN112538101B (zh) * 2020-08-13 2026-02-03 常州博海威医药科技股份有限公司 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN113292619B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸-异烟碱共晶体及其组合物
CN115368423B (zh) * 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016135750A (ja) 2015-01-23 2016-07-28 株式会社ベスビオ 化粧料
JP2021524865A (ja) 2018-05-15 2021-09-16 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗加齢剤としての、特に不妊症治療のためのニコチンアミドモノヌクレオチドの無機塩
JP2021533195A (ja) 2018-08-01 2021-12-02 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗老化剤としてのニコチン酸及びニコチンアミドモノヌクロエチド及びリボシドの四級アンモニウム塩
CN109350622A (zh) 2018-10-17 2019-02-19 深圳市龙格生技术有限公司 烟酰胺核糖及其衍生物与吡咯喹啉醌及其钠盐的组合工艺
WO2021098725A1 (en) 2019-11-19 2021-05-27 Tsinghua University Synthetic method for nmn derivative and medical applications of nmn and its derivative
CN113490676A (zh) 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用
CN114075582A (zh) 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种d-核糖-5-磷酸的制备方法和应用
CN113332304A (zh) 2021-06-08 2021-09-03 深圳市旷逸生物科技有限公司 烟酰胺单核苷酸在制备心肌缺血再灌注损伤药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
芦澤一英，医薬品の多形現象と晶析の化学，2002年，pp.273,278,305-317

Also Published As

Publication number Publication date
CN118525027A (zh) 2024-08-20
US20250163092A1 (en) 2025-05-22
EP4484438A1 (en) 2025-01-01
CN115368423A (zh) 2022-11-22
CA3244879A1 (en) 2025-06-13
NZ813980A (en) 2026-01-30
AU2023223327B2 (en) 2025-10-09
US12570683B2 (en) 2026-03-10
KR20240167631A (ko) 2024-11-27
AU2023223327A1 (en) 2024-09-12
JP2025508874A (ja) 2025-04-10
WO2023160405A1 (zh) 2023-08-31
CN115368423B (zh) 2025-05-09

Similar Documents

Publication Publication Date Title
JP7762933B2 (ja) 還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用
JP6967625B2 (ja) ゲムシタビンリン酸ジアステレオ異性体を分離する方法
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
CZ281318B6 (cs) Monohydrát mometasonfuroátu, způsob přípravy této látky a přípravy lékových kompozic z ní
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
WO2016155473A1 (zh) 一种mek激酶抑制剂的对甲苯磺酸盐、其结晶形式及制备方法
US20250388616A1 (en) POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR
JP2024503442A (ja) 塩メタセシスによるニコチンアミドリボフラノシド塩の製造方法、そのトシレート塩の結晶形態及びそのクロリド：ヨージド塩の共結晶化した形態
WO2011007870A1 (ja) ２－［［［２－［（ヒドロキシアセチル）アミノ］－４－ピリジニル］メチル］チオ］－ｎ－［４－（トリフルオロメトキシ）フェニル］－３－ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法
US20260015377A1 (en) Crystalline form i of reduced nicotinamide mononucleotide disodium monohydrate and preparation method therefor
KR102458566B1 (ko) 메푸파리브 히드로클로라이드 다결정형 물질 및 이의 제조방법과 응용
MXPA04009009A (es) Pseudopolimorfos isoestructurales de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a.
CN118324648A (zh) (r)-特布他林苯磺酸盐a晶型和b晶型及其制备方法
CN119978042B (zh) 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
HK40121709A (zh) 还原型β-烟醯胺单核苷酸钙盐的无定型及其制法和用途
CN110964017A (zh) 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途
CN109422723B (zh) 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
EP3368506B1 (en) Process for the preparation of enclomiphene citrate having needle shaped crystal habit.
HK40119630A (zh) 烟酰胺呋喃核糖苷盐的结晶形式以及包含其的营养补充剂和药物组合物
WO2025203051A1 (en) Ribociclib succinate form c and process thereof
WO2015062481A1 (zh) 替莫唑胺晶型及其制备方法
CN119219718A (zh) 一种nmnh钙盐、其晶型及用途
CN114957382A (zh) 氘代尼马瑞韦晶型i及其制备方法
JP2023552672A (ja) ヌクレオシド類似体の塩及びその結晶形、医薬組成物並びに用途
HK1238251B (zh) 烟酰胺核苷的结晶形式

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251013

R150 Certificate of patent or registration of utility model

Ref document number: 7762933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150